Mads Haugland Haugen

6PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersComputational physiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 14, 2026
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer.

|May 25, 2026
Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer.

|Nov 24, 2025
Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Maria Aanesland Dahle, Jan-Lukas Førde, Eivind Valen Egeland

|Apr 27, 2024
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill

|Mar 27, 2023
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.

Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg

|Dec 25, 2019
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.

Karine Flem-Karlsen, Erin McFadden, Nasrin Omar

Pageof 1

Frequent Collaborators

3 joint publications

Gunhild M Mælandsmo

2 joint publications

Olav Engebraaten

2 joint publications

Lina Prasmickaite

2 joint publications

Anne-Lise Børresen-Dale